What's Happening?
Daiichi Sankyo and AstraZeneca's TROP2-directed antibody drug conjugate, Datroway, has received approval from the European Union for use as a first-line treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC)
who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on the results of the TROPION-Breast02 phase 3 trial, which demonstrated a statistically significant improvement in overall survival and progression-free survival compared to chemotherapy. Datroway is the first TROP2-directed ADC to show an overall survival benefit in this patient group, providing a new treatment option for those with limited alternatives.
Why It's Important?
The approval of Datroway in the EU is significant as it offers a new treatment option for patients with metastatic TNBC, a particularly aggressive form of breast cancer with limited treatment options. This development is crucial as more than two-thirds of patients with metastatic TNBC are not candidates for immunotherapy, leaving chemotherapy as the standard treatment. The introduction of Datroway, which has shown a survival benefit, represents a meaningful advancement in the treatment landscape for this patient population, potentially improving outcomes and quality of life for many patients.
What's Next?
Following the EU approval, Daiichi Sankyo and AstraZeneca are expected to focus on the commercial rollout of Datroway across Europe. Additionally, ongoing reviews in other regions, including China, Japan, and several countries under Project Orbis, are anticipated. The companies will likely continue to explore further indications and combinations for Datroway, aiming to expand its use and benefit more patients globally.
